Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Specified Use-Results Study of Ilaris in Schnitzler's Syndrome
jRCT2031260196Recruiting
- Sponsor
- Novartis
- Start
- May 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of canakinumab in Schnitzler syndrome, sponsored by Novartis. Primary endpoints: Complete clinical response rate (7 days to 8 weeks), Partial or complete clinical response over 48 weeks and 5 more. Started May 2026; status: recruiting.
02
Drugs
canakinumab
03
Conditions
Schnitzler syndrome
Beyond the preview
Go deeper on jRCT2031260196.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260196.